Chemical andropause and amyloid-β peptide [3]

JAMA

Volumn 285, Issue 17, 2001, Pages 2195-2196

  Gandy, S ^a   Almeida, O P ^a   Fonte, J ^a   Lim, D ^a   Waterrus, A ^a   Spry, N ^a   Flicker, L ^a   Martins, R N ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ESTRADIOL; FLUTAMIDE; LEUPRORELIN; TESTOSTERONE;

ADENOCARCINOMA; ADULT; AGED; ALZHEIMER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HORMONE INHIBITION; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; LETTER; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TESTOSTERONE BLOOD LEVEL;

EID: 0035795715     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.17.2195-a     Document Type: Letter

References (6)

1. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
2. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides
3. Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides
4. Ovariectomy and 17-beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain
5. Plasma amyloid beta-peptide and incipient Alzheimer's disease
6. Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees